Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection

Gastroenterology

Volumn 152, Issue 6, 2017, Pages 1366-1371

  Gane, Edward J ^a   Hyland, Robert H ^b   Yang, Yin ^b   Svarovskaia, Evguenia ^b   Stamm, Luisa M ^b   Brainard, Diana M ^b   McHutchison, John G ^b   Stedman, Catherine A M ^c  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b GILEAD SCIENCES   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antiviral agents; Direct acting antivirals; NS5A inhibitor; Polymerase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG COMBINATION; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RASH; RELAPSE; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG COMBINATIONS; FATIGUE; FEMALE; FLUORENES; GENOTYPE; HEADACHE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; NAUSEA; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85018854353     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.01.017     Document Type: Article

References (13)

1. 1 Gower, E., Estes, C.C., Hindman, S., et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol 61 (2014), S45–S57.
2. 2 Lawitz, E., Mangia, A., Wyles, D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
3. 3 Jacobson, I.M., Gordon, S.C., Kowdley, K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368 (2013), 1867–1877.
4. 4 Zeuzem, S., Dusheiko, G.M., Salupere, R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370 (2014), 1993–2001.
5. 5 Koff, R.S., Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 39 (2014), 478–487.
6. 6 Le, T.K., Macaulay, D., Kalsekar, A., et al. Costs and resource utilization associated with anemia and rash in chronic hepatitis C patients treated with direct-acting antiviral agents in the United States. Clin Ther 37 (2015), 1713–1725.
7. 7 Lawitz, E.J., Gruener, D., Hill, J.M., et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57 (2012), 24–31.
8. 8 Wong, K.A., Worth, A., Martin, R., et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57 (2013), 6333–6340.
9. 9 Donaldson, E.F., Harrington, P.R., O'Rear, J.J., et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61 (2015), 56–65.
10. 10 Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
11. 11 Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
12. 12 Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
13. 13 US Food and Drug Administration, Center for Drug Evaluation and Research. Virology review, sofosbuvir and ledipasvir. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000MicroR.pdf. Accessed May 17, 2016.